| 摘要 |
<p>A therapeutic agent said agent being an agonist to a receptor of the cytokine receptor family such as the hβc or common β receptor of IL-3, IL-5 and GM-CSF. Each of the members of the cytokine receptor family having an extracellular receptor module (CRM) composed of two discrete folding domains (CRD). It has been found that a first of the two CRDs, in the case of hβc being β4, is a switching CRD so that conformational changes in the switching CRD lead to activation. A second of the CRDs, in the case of hβc being β3, being an inhibiting CRD. Under normal conditions the CRM is in an inactive state unless activated by ligand. The agonist property being a result of a change in the switching CRD from its inactive state to an active state leading to a signal being produced to effect said agonist property, and may be a result of blocking the inhibitory effect of the inhibiting CRD on the switching CRD or may be a result of inducing a change to the switching CRD by itself.</p> |
